APA (7th ed.) Citation

Saura, C., Cortés, J., Modi, S., Kim, S., Hamilton, E., Hurvitz, S., . . . André, F. (2026). Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03. Annals of Oncology, 37(3), 353. https://doi.org/10.1016/j.annonc.2025.11.007

Chicago Style (17th ed.) Citation

Saura, C., et al. "Pooled Analysis by Best Confirmed Response to Trastuzumab Deruxtecan and Related Biomarkers in Patients with HER2-positive Metastatic Breast Cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03." Annals of Oncology 37, no. 3 (2026): 353. https://doi.org/10.1016/j.annonc.2025.11.007.

MLA (9th ed.) Citation

Saura, C., et al. "Pooled Analysis by Best Confirmed Response to Trastuzumab Deruxtecan and Related Biomarkers in Patients with HER2-positive Metastatic Breast Cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03." Annals of Oncology, vol. 37, no. 3, 2026, p. 353, https://doi.org/10.1016/j.annonc.2025.11.007.